MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
common stock options...
$5,292K
Net cash provided by
financing activities
$4,945K
Canceled cashflow
$347K
Net increase
(decrease) in cash, cash...
-$378,271K
Canceled cashflow
$4,945K
Maturities of short-term
investments
$405,284K
Stock-based compensation
$40,221K
Accrued expenses
$6,290K
Depreciation
$2,029K
Accounts payable
$977K
Other long-term
assets
-$276K
Proceeds from the
issuance of common stock...
-$347K
Net cash used in
investing activities
-$300,981K
Net cash used in
operating activities
-$82,235K
Canceled cashflow
$405,284K
Canceled cashflow
$49,793K
Purchases of short-term
investments
$705,222K
Net loss
-$113,625K
Purchases of property and
equipment
$1,043K
Accretion of discounts on
investments, net
$17,574K
Prepaid expenses and
other current assets
$827K
Operating lease
right-of-use assets and...
$2K
Back
Back
Cash Flow
source: myfinsight.com
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)